Stockscreener 앱 받기
7.78
1.64%
-0.13
전일 마감가:
$7.91
열려 있는:
$7.87
하루 거래량:
19,082
Relative Volume:
0.27
시가총액:
$439.34M
수익:
$154.57M
순이익/손실:
$15.07M
주가수익비율:
28.81
EPS:
0.27
순현금흐름:
$10.92M
1주 성능:
+4.71%
1개월 성능:
-2.14%
6개월 성능:
+8.21%
1년 성능:
+33.68%
1일 변동 폭
$7.78
$7.90
1주일 범위
$7.37
$7.91
52주 변동 폭
$5.08
$9.155
Kamada Ltd Stock (KMDA) Company Profile
KMDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.78 | 439.34M | 154.57M | 15.07M | 10.92M | 0.27 |
|
ZTS
Zoetis Inc
|
152.82 | 68.32B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.66 | 46.55B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.85 | 43.80B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.33 | 19.01B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
306.41 | 13.79B | 2.99B | 1.21B | 1.13B | 25.06 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 개시 | The Benchmark Company | Buy |
| 2024-07-03 | 개시 | Stifel | Buy |
| 2018-02-02 | 개시 | Chardan Capital Markets | Buy |
Kamada Ltd 주식(KMDA)의 최신 뉴스
What drives Kamada Ltd. stock priceSpectacular growth rates - Autocar Professional
What analysts say about Kamada Ltd. stockExceptional growth trajectory - jammulinksnews.com
Is Kamada Ltd. a good long term investmentBreakthrough capital growth - jammulinksnews.com
What makes Kamada Ltd. stock price move sharplyHigh Potential Safe Trades - Newser
Kamada Ltd. Stock Analysis and ForecastOutstanding yields - jammulinksnews.com
Why Kamada Ltd. stock attracts strong analyst attentionFree Real-Time Trading Opportunities - Newser
How Kamada Ltd. stock performs during market volatilityProfitable Yet Secure Picks - Newser
Emphysema Pipeline 2025: MOA, ROA, and Clinical Trial Insights - openPR.com
Emphysema Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi - The Globe and Mail
Emphysema Pipeline 2025: MOA, ROA, And Clinical Trial Insights Explored By Delveinsight Kamada, Ltd., Hoffmann-La Roche, Aeris Therapeutics, Grifols Therapeutics, Sanofi - MenaFN
Is Kamada (KMDA) Stock Undervalued Right Now? - Nasdaq
Kamada confirms continuous business operations despite recent events in Middle East - MSN
Should Value Investors Buy Kamada (KMDA) Stock? - Yahoo Finance
Kamada Confirms Continuous Global Business Operations and - GlobeNewswire
Kamada Ensures Global Operations Amid Middle East Tensions - TipRanks
Kamada confirms continuous business operations despite Middle East events - TipRanks
Kamada Confirms No Supply Disruptions: How Israeli Biotech Giant Safeguards Global Product Availability - Stock Titan
Plasma Therapeutics Market Revenue to Attain USD 46.46 Bn by 2033 - Precedence Research
Kamada Reports Strong Q1 2025 Growth with Plasma Business Expansion and Key Milestones - citybuzz -
Implied Volatility Surging for Kamada Stock Options - Yahoo Finance
Kamada Intensifies Efforts to Highlight CYTOGAM's Role in Combatting CMV in Organ Transplant Patients - citybuzz -
Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAM - FinancialContent
Millennium Management LLC Sells 36,872 Shares of Kamada Ltd. (NASDAQ:KMDA) - Defense World
Are Investors Undervaluing Kamada (KMDA) Right Now? - Yahoo Finance
Alpha-1 Antitrypsin Deficiency Market: Epidemiology, - openPR.com
Kamada (NASDAQ:KMDA) Stock Crosses Below 200 Day Moving Average – What’s Next? - Defense World
Kamada (NASDAQ:KMDA) Stock Rating Upgraded by Wall Street Zen - Defense World
Kamada's (TLV:KMDA) Solid Earnings Are Supported By Other Strong Factors - simplywall.st
Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm - The Manila Times
HC Wainwright Issues Optimistic Outlook for Kamada Earnings - Defense World
Kamada Ltd (KMDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.25%
0.75%
자본화:
|
볼륨(24시간):